TempusAI is making significant strides in cancer treatment through the integration of AI and extensive data analytics.
Founded a decade ago, TempusAI is focused on harnessing artificial intelligence to enhance precision medicine in oncology. CEO Eric Lefkofsky emphasizes the necessity of vast proprietary data and a robust distribution system to effectively deliver insights to healthcare providers and patients. TempusAI claims to have established a unique ecosystem that generates and utilizes clinical data, connecting with approximately two-thirds of U.S. academic medical centers. This extensive network allows the company to match patients with appropriate therapies and clinical trials efficiently.
TempusAI has amassed over 500 petabytes of data from more than 45 million patients, including a substantial collection of digitized pathology and imaging records. This wealth of information is pivotal for developing insights that can inform treatment decisions and enhance research efforts. The company’s Hub platform integrates with major electronic health records, enabling physicians to access AI-driven insights seamlessly.
TempusAI operates two main business segments: diagnostics and data analytics. The diagnostics arm aims to improve the accuracy of test results through AI, ensuring that treatments are tailored to individual patient histories. Meanwhile, the data business focuses on extracting and synthesizing information from the healthcare system to provide actionable insights for both clinicians and biopharma companies. With over $2 billion in data licensing agreements with major pharmaceutical firms, TempusAI is poised to play a crucial role in the future of drug discovery and development, reinforcing the idea that technology will inevitably transform healthcare.